In order to mitigate the economic consequences of the coronavirus pandemic, various economic and financial policy measures have been announced, initiated and adopted at federal and state leven since mid-March 2020. The number of aid and relief measures continues to grow almost daily.
This GSK Update intends to regularly provide an overview of all of the different aid measures.
Press contact
Christine Ström
+49 30 203907-7763
presse@gsk.de
Dr. Katy Ritzmann
Partner*
+49 30 203907-422
katy.ritzmann@gsk.de
Dr. Thomas Derlin, LL. M.
Partner*
+49 30 203907-0
thomas.derlin@gsk.de
Dr. Jan Hennig
Partner*
+49 30 203907-81
jan.hennig@gsk.de
Prof. Dr. Jan Kehrberg
Partner*
+49 30 203907-123
jan.kehrberg@gsk.de
Annika Abenhardt
Associate
+49 30 203907-0
annika.abenhardt@gsk.de
Dr. h.c. Hans-Joachim Otto
Of Counsel
+49 69 710003-131
hans-joachim.otto@gsk.de
Dr. Markus Söhnchen
Partner*
+49 69 71003-0
markus.soehnchen@gsk.de
Dr. Petra Eckl
Partner*
+49 69 710003-0
petra.eckl@gsk.de
Max Wilmanns, LL.M.
Partner*
+49 40 369703-0
max.wilmanns@gsk.de
Dr. Arne Gniechwitz
Partner*
+49 40 369703-0
arne.gniechwitz@gsk.de
Dr. Andreas C. Peters, LL.M.
Local Partner*
+49 40 369703-0
andreas.peters@gsk.de
Dr. Raoul Kreide
Local Partner*
+49 6221 4566-0
raoul.kreide@gsk.de
Dr. Andreas Bauer, LL.M.
Partner*
+49 89 288174-74
andreas.bauer@gsk.de
Dipl.-Kfm. Univ. Josef Schmid
Partner*
+49 89 288174-674
josef.schmid@gsk.de
Andreas Dimmling
Partner*
+49 89 288174-73
andreas.dimmling@gsk.de
